Envelope fusion vectors for use in gene delivery

Chemistry: molecular biology and microbiology – Vector – per se

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435325, 435 697, 435 695, 435 6951, 435 6952, 435 912, 435 6, 424 9321, 514 44, 5303871, 530350, 536 235, 536 2431, C12N 1563

Patent

active

057363870

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to retroviral vectors useful for introducing polynucleotides into target cells and more specifically to retroviral particles having on their surface chimeric targeting proteins capable of both binding to specific target cells via cellular cytokine receptors and mediating vector entry into the targeted cells.


BACKGROUND OF THE INVENTION

Retroviruses are a family of RNA viruses that contain RNA-directed DNA polymerase activity. These viruses possess similar structural characteristics, being membranous, icosahedral particles that are 70-120 nM in diameter and contain RNA as well as the structural and catalytic proteins necessary for infection of a host cell and subsequent reverse transcription of the viral genome. Retroviruses that are secreted from cells can be categorized into B-, C-, and D-type, lentiviruses, spumaviruses, and others, based on criteria relating to the shape of the nucleocapsid core within the particle, the nature of the budding process and the complexity of the viral genome, see, e.g., Weiss, R., et al., (1984 and 1985) "RNA Tumor Viruses," Cold Spring Harbor, N.Y.
Retroviruses typically have three common open reading frames, gag, pol and env, which encode the structural proteins, enzymatic activities including reverse transcriptase, and envelope proteins, respectively. The product of the env gene is a polyprotein precursor (typically referred to herein as the "envelope protein" or the "env protein"), that is proteolytically cleaved during transport to yield two polypeptides: a glycosylated protein found on the external surface of the particle (the "SU" protein), and a membrane-spanning or transmembrane protein (the "TM" protein); see, e.g., Hunter, E. and R. Swanstrom, Curr. Topics Microbiol. Immunol. 157:187-253, 1990. The SU protein is involved in recognizing and binding to cellular receptors, while the TM protein is involved in mediating the fusion of viral and cellular membranes necessary for viral uptake, id.
A retroviral vector is an infectious viral particle useful in achieving stable and efficient transduction of a gene into mammalian cells, including some cells that are not readily transfectable by other methods, such as primary cells of various types and also cells in vivo. Retroviral vectors based on murine C-type retroviruses have been used successfully for a number of years to introduce and express genes in cultured mammalian cells. Typically, retroviral vectors are produced by "packaging cell lines" that provide the necessary retroviral gag, pol and env gene products in trans, see, e.g., Miller et al., Human Gene Therapy 1:5-14 (1990); and Ausubel, F. M. et al. (eds), Units 9.10-9.14 in "Current Protocols in Molecular Biology," John Wiley & Sons, New York, 1992. This approach results in the production of retroviral particles which are highly infectious for mammalian cells, but are incapable of further replication after they have integrated into the genome of the target cell. Gene therapy protocols using retroviral vectors generally rely on a cell line containing the gag and pol genes, along with the env genes from an "amphotropic" (i.e. broad host range) virus such as 4070A amphotropic virus, which yields amphotropic progeny virus (e.g., the "PA317" cell line described by Miller and Buttimore, Mol. Cell. Biol. 6:2895, 1986).
Gene therapy protocols typically are ex vivo in nature, in that they require harvesting cells from the patient, culturing them in vitro, transducing them with the retroviral vector and returning the transduced cells to the patient; see, e.g., Kasid et al., Proc. Natl. Acad. Sci. USA 87:473, 1990; and Rosenberg et al., N. Engl. J. Med. 323:570, 1990.
In many situations, it would be desirable to restrict viral infection to a specific sub-population of the exposed cells. In such circumstances, the broad host range typical of retroviruses presents a substantial problem. Even where it is possible to purify the desired target cells, either before or after transduction, this necessitates undesirable manipulation

REFERENCES:
Coghlan, Focus, vol. 148, pp. 14-15, Nov. 25, 1995.
Brown, "News Media, Researchers `Oversold`Gene Therapy, Advisory Panel Says", The Washington Post, Dec. 8, 1995.
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 7, 1995.
Hunter et al., "Retrovirus envelope glycoproteins" Current Topics in Microbiology and Immunology (1990) 157:187-253.
Ausbel et al., eds., "Transduction of genes using retrovirus vectors" Current Protocols in Molecular Biology (1992) John Wiley & Sons's, New York, Section III, pp. 9.10.1-9.14.3.
Vile et al., "A murine cell line producing HTLV-1 pseudotype virions carrying a selectable marker gene" Virology (1991) 180:420-424.
Miller et al., "Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus" J. Virol. (1991) 65(5):2220-2224.
Landau et al., "Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range" J. Virol. (1991) 65(1):162-169.
Emi et al., "Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis viris" J. Virol. (1991) 65(3):1202-1207.
Dong et al., "A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range" J. Virol. (1992) 66(12):7374-7382.
Kim et al., "Transport of cationic amino acids by the mouse ecotropic retrovirus receptor" Nature (1991) 352:725-728.
Johann et al., "GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus" J. Virol. (1992) 66(3):1635-1640.
Ban et al., "Isolation and characterization of a 2.3-kilobase-pair cDNA fragment encoding the binding domain of the bovine leukemia virus cell receptor" J. Virol. (1993) 67(2):1050-1057.
Russell et al., "Retroviral vectors displaying functional antibody fragments" Nucl. Acids Res. (1993) 21(5):1081-1085.
Roux et al., "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of Human cell by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses" Proc. Natl. Acad. Sci. USA (1989) 86:9079-9083.
Etienne-Julan et al., "the efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell" J. Gen. Virol. (1992) 73:3251-3255.
Arai et al., "Cytokines: coordinators of immune and inflammatory responses" Annu. Rev. Biochem. (1990) 59:783-836.
Battini et al., "Receptor choice determinants in the envelope glycorproteins of amphotropic, xenotropic , and polytropic murine leukemia viruses" J. Virol. (1992) 66(3):1468-1475.
Gillis et al., "T cell growth factor: parameters of production and a quantitative microassay for activity" J. Immunol. (1978) 120 (6):2027-2032.
Goud et al., "Antibody-mediated binding of a murine ecotropic moloney retroviral vector to human cells allows internalization but not the establishment of the proviral state" Virology (1988) 163:251-254.
Hatakeyama et al., "Interleukin-2 receptor .beta. chain gene: generation of three receptor forms by cloneduman .alpha. and .beta. chain cDNA'" Science (1989) 244:551-71.556.
Linial et al., "Retroviral RNA packaging: sequence requirements and implications" Current Topics in Microbiology and Immunology (1990) 157:125-152.
Lupton et al., "Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene" Mol. Cell. Biol. (1991) 11(6):3374-3378.
Matthews et al., "A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations" Cell (1991) 65:1143-1152.
Miller et al., "Two base changes restore infectivity to a noninfectious molecular clone of moloney murine leukemia virus (pMLV-1) J. Virol. (1984) 49(1):214-222.
Miyajima et al., "Cytokine receptors and signal transduction" Annu. Rev. Immunol.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Envelope fusion vectors for use in gene delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Envelope fusion vectors for use in gene delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Envelope fusion vectors for use in gene delivery will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-12055

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.